GSK GlaxoSmithKline
- 34.080
- -0.040-0.12%
- 34.080
- 0.0000.00%
GlaxoSmithKline News
6-K: Transaction Notification
6-K: Block Listing Application
6-K: Gsk Announces First Trial Met Its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer
6-K: Jemperli (Dostarlimab) Receives Us Fda Breakthrough Therapy Designation for Locally Advanced Dmmr/Msi-H Rectal Cancer
6-K: Gsk's B7-H3-Targeted Antibody-Drug Conjugate, Gsk'227, Receives Ema Priority Medicines (Prime) Designation in Relapsed Extensive-Stage Small-Cell Lung Cancer
6-K: Jemperli (Dostarlimab) Plus Chemotherapy Receives Positive Chmp Opinion to Expand Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer
6-K: Transaction Notification
6-K: Blenrep Shows Significant Overall Survival Benefit, Reducing the Risk of Death by 42% in Multiple Myeloma at or After First Relapse
6-K: Blenrep Combination Accepted for Priority Review in China in Relapsed/Refractory Multiple Myeloma
6-K: Us Fda Accepts Gsk's Submission for the Use of Nucala (Mepolizumab) in Copd
6-K: Gsk and Zhifei Revise and Extend Strategic Vaccine Collaboration in China
6-K: Transaction Notification
6-K: Total Voting Rights and Capital
6-K: Gsk's Fully Liquid Menveo Meningococcal Vaccine Approved by European Commission
6-K: Blenrep Combinations Accepted for Review by the Us Fda for the Treatment of Relapsed/Refractory Multiple Myeloma
6-K: Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe Rsv Disease in Japan
6-K: Transaction Notification
6-K: Linerixibat Shows Positive Phase Iii Results in Cholestatic Pruritus in Primary Biliary Cholangitis
6-K: Lenrep Shows Overall Survival Benefit in Head-to-Head Dreamm-7 Phase Iii Trial for Relapsed/Refractory Multiple Myeloma
6-K: Block Listing Six Monthly Return
No Data
